This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASC30 injection
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
115
Drug: ASC30 injection, for subcutaneous use Drug: Placebo injection, for subcutaneous use
Ascletis clinical site
San Antonio, Texas, United States
Incidence of AEs, SAEs (Safety and tolerability) of ASC30
A summary of AEs, SAEs and other non-serious adverse events
Time frame: Up to Day169
Cmax of ASC30
PK parameters of ASC30
Time frame: Up to Day169
Change From Baseline in Body Weight
Change From Baseline in Body Weight
Time frame: Up to Day169
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.